62 related articles for article (PubMed ID: 2130019)
1. [The significance of determination of NK cell activity in malignant diseases].
Spuzić I; Konjević G
Glas Srp Akad Nauka Med; 1990; (39):153-60. PubMed ID: 2130019
[TBL] [Abstract][Full Text] [Related]
2. [The effect of serum on NK cell activity].
Konjević G; Spuzić I
Glas Srp Akad Nauka Med; 1991; (41):113-20. PubMed ID: 1916438
[TBL] [Abstract][Full Text] [Related]
3. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of different effects of sera of breast cancer patients on the activity of natural killer cells.
Konjević G; Spuzić I
J Clin Lab Immunol; 1992; 38(2):83-93. PubMed ID: 1343351
[TBL] [Abstract][Full Text] [Related]
5. [Immunomodulatory effect of serum on NK cells in vitro in healthy individuals].
Konjević G; Spuzić I
Glas Srp Akad Nauka Med; 1994; (44):45-54. PubMed ID: 7590414
[TBL] [Abstract][Full Text] [Related]
6. [The possibilities of modulation of NK cell activity].
Konjević G; Spuzić I
Glas Srp Akad Nauka Med; 2002; (47):89-101. PubMed ID: 16078444
[TBL] [Abstract][Full Text] [Related]
7. Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer.
Konjević G; Spuzić I
Neoplasma; 1993; 40(2):81-5. PubMed ID: 8350959
[TBL] [Abstract][Full Text] [Related]
8. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
9. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
[TBL] [Abstract][Full Text] [Related]
11. Modulation of natural killer cell activity by serum from cancer patients: preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer.
Pislarasu M; Oproiu A; Taranu D; Herberman RB; Sulica A
Cancer Res; 1988 May; 48(9):2596-603. PubMed ID: 3356020
[TBL] [Abstract][Full Text] [Related]
12. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients.
Brenner BG; McCrea EL; Margolese RG
Anticancer Res; 1988; 8(4):653-8. PubMed ID: 3263077
[TBL] [Abstract][Full Text] [Related]
13. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
[TBL] [Abstract][Full Text] [Related]
14. In vitro enhancement of peripheral blood mononuclear cell natural killer activity following short term incubation with fetal calf serum.
Lauer SJ; Finlan J; Borella LD; Piaskowski VD; Casper JT
J Clin Lab Immunol; 1983 Oct; 12(2):105-10. PubMed ID: 6606047
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of interleukin-2 on natural killer activity in lung cancer patients.
Ito M; Suzuki H; Yamashita N; Sugiyama E; Maruyama M; Sato M; Iwata M; Yano S
Anticancer Res; 1984; 4(6):375-8. PubMed ID: 6097158
[TBL] [Abstract][Full Text] [Related]
16. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
[TBL] [Abstract][Full Text] [Related]
17. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
[TBL] [Abstract][Full Text] [Related]
19. Role of natural killer cells in cancer.
Pross HF; Lotzová E
Nat Immun; 1993; 12(4-5):279-92. PubMed ID: 8257832
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
